Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12671375 | 0.97 | GSK3B (0.44) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1417911 | 0.90 | GSK3B (0.43) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL7984308 | 0.84 | DAPK3 (0.33) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL7978767 | 0.84 | DAPK3 (0.42) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1417971 | 0.84 | DAPK3 (0.45) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL7982960 | 0.84 | DAPK3 (0.45) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL7985441 | 0.82 | DAPK3 (0.44) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL12671286 | 0.80 | DAPK3 (0.47) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL7985587 | 0.77 | DAPK3 (0.32) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL7980967 | 0.77 | DAPK3 (0.44) | DAPK3NTRK1PIM1FLT3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | DAPK3 518/4885NTRK1 2692/4885PIM1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.